U.S. markets closed

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3300-0.0300 (-1.27%)
At close: 04:00PM EDT
2.4000 +0.07 (+3.00%)
After hours: 05:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.3600
Bid2.3300 x 4000
Ask2.4100 x 800
Day's Range2.3000 - 2.3999
52 Week Range2.2400 - 11.2500
Avg. Volume31,157
Market Cap20.545M
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-1.4370
Earnings DateFeb 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ONVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organovo Holdings, Inc.
    DDD: Raising target price to $9.003D SYSTEMS CORP has an Investment Rating of SELL; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • GlobeNewswire

    Organovo Achieves 3D Tissue Model for Crohn’s Disease

    SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease. Based on its internal data and scientific results, the company believes that its first IBD mo

  • Motley Fool

    Why Organovo Holdings, Inc. Stock Soared 49.7% This Week

    The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.

  • GlobeNewswire

    UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

    SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting